1-3 of 3
Daniel Betticher
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

High-Dose Chemotherapy with Bendamustin and Melphalan Improves the Rate of Complete Remission in Myeloma Patients in First Remission Compared to Standard Melphalan Alone

Sarah Farag, Ulrike Bacher, Myriam Legros, Daniel Betticher, Jean-Marc Lüthi, Thomas Egger, Thilo Zander, MD, Barbara Jeker, Thomas Pabst, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 39–40.
https://doi.org/10.1182/blood-2020-141545
Published: 2020
Journal Articles

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Clinical Trials & Observations
Christoph Driessen, Rouven Müller, Urban Novak, Nathan Cantoni, Daniel Betticher, Nicolas Mach, Axel Rüfer, Ulrich Mey, Panagiotis Samaras, Karin Ribi, Lenka Besse, Andrej Besse, Catherine Berset, Stephanie Rondeau, Hanne Hawle, Felicitas Hitz, Thomas Pabst, Thilo Zander
Journal: Blood
Blood (2018) 132 (19): 2097–2100.
https://doi.org/10.1182/blood-2018-05-851170
Published: 2018
Includes: Supplemental data
Journal Articles

The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13)

Christoph Driessen, MD PhD, Rouven Müller, MD, Urban Novak, MD, Nathan Cantoni, MD, Daniel Betticher, Nicolas Mach, Michael Gregor, Panagiotis Samaras, MD, Catherine Berset, Stephanie Rondeau, Hanne Hawle, MD, Felicitas Hitz, MD, Thomas Pabst, MD PhD, Thilo Zander, MD
Journal: Blood
Blood (2016) 128 (22): 487.
https://doi.org/10.1182/blood.V128.22.487.487
Published: 2016